TGFB1 and plasma cell myeloma: The inhibitory effect of NTZ on bone metastasis could apply to other types of malignancies where bone metastasis frequently occurs, and TGF-β is an inducer, including the carcinomas of the breast, lung, and prostate and multiple myeloma [46, 47].